Form 4: Cytosorbents CEO Phillip Chan Reports Acquisition and Expiration of Warrants
SEC Form 4 Filing
Phillip Chan, CEO of Cytosorbents, reports the acquisition of common stock and Series A Right Warrants through a rights offering, as well as the expiration of unexercised warrants.
Summary
- Phillip Chan, the CEO of Cytosorbents Corp, filed a Form 4 detailing changes in beneficial ownership.
- On January 17, 2025, Chan exercised subscription rights from a rights offering, acquiring common stock and warrants.
- The rights offering, which closed on January 10, 2025, allowed Chan to receive units consisting of common stock, Series A Warrants, and Series B Warrants at $1.00 per unit.
- Chan acquired 34,168 shares of common stock and 34,168 Series A Right Warrants at an exercise price of $1.13.
- The exercise price of the Series A Right Warrants was calculated based on 90% of the 5-day volume-weighted average price of Cytosorbents' common stock prior to the expiration date, with a floor of $1.00 and a ceiling of $2.00.
- 56,664 Series A Warrants expired unexercised on February 24, 2025.
- Chan directly owns 1,277,363 shares of Common Stock.
- Chan also holds various Restricted Stock Units (RSUs) that vest over time or upon a change in control of the company.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing primarily reports transactions related to a rights offering and warrant expiration. The CEO's participation in the rights offering is a positive signal, but the warrant expiration is a minor negative.
Positives
- The CEO's participation in the rights offering demonstrates confidence in the company's future.
Negatives
- The expiration of 56,664 Series A warrants unexercised could indicate a lack of short-term confidence that the share price would exceed the exercise price.
Risks
- The vesting of RSUs is contingent upon continued service, creating a potential risk if the Reporting Person leaves the company.
- The vesting of some RSUs is tied to a 'Change In Control', which may or may not occur.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor the actions of key personnel.
Comparison to Industry Standards
- Executive compensation packages, including RSUs and stock options, are common in the biotechnology industry to incentivize performance and align management interests with those of shareholders.
- Rights offerings are a relatively common method for companies, particularly smaller ones, to raise capital.
Stakeholder Impact
- The CEO's transactions may influence investor sentiment and potentially impact the stock price.
- The rights offering impacts existing shareholders by potentially diluting their ownership.
Key Dates
| Date | Description |
|---|---|
| 2015-04-08 | Grant date of 130,000 RSUs that will be settled into shares of Common Stock upon vesting upon a 'Change In Control' of the Company |
| 2016-06-07 | Grant date of 57,000 RSUs that will be settled into shares of Common Stock upon vesting upon a 'Change In Control' of the Company |
| 2017-02-24 | Grant date of 18,700 RSUs that will be settled into shares of Common Stock upon vesting upon a 'Change In Control' of the Company |
| 2018-03-15 | Grant date of 10,300 RSUs that will be settled into shares of Common Stock upon vesting upon a 'Change In Control' of the Company |
| 2023-07-07 | Grant date of 87,000 RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant |
| 2024-04-02 | Grant date of 96,000 RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant |
| 2025-01-10 | Closing date of the Rights Offering. |
| 2025-01-17 | Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering |
| 2025-02-24 | Date of transaction: Acquisition of common stock and Series A Right Warrants; Expiration of unexercised Series A Warrants. |
| 2025-02-26 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.